NEW YORK (
) hit a new 52-week low Tuesday as it is currently trading at $4.36, below its previous 52-week high of $6.40 with 1.2 million shares traded as of 11:52 a.m. ET. Average volume has been 1.5 million shares over the past 30 days.
Geron has a market cap of $599.8 million and is part of the
industry. Shares are down 13.3% year to date as of the close of trading on Monday.
Geron Corporation, a biopharmaceutical company, develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes.
- Practice your GERN trading strategies and win cash in our stock game.
TheStreet Ratings rates Geron as a
. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. You can view the full
or get investment ideas from our